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Abstract
Background:  La Crosse virus (LACV), family Bunyaviridae, was first identified as a human
pathogen in 1960 after its isolation from a 4 year-old girl with fatal encephalitis in La Crosse,
Wisconsin. LACV is a major cause of pediatric encephalitis in North America and infects up to
300,000 persons each year of which 70–130 result in severe disease of the central nervous system
(CNS). As an initial step in the establishment of useful animal models to support vaccine
development, we examined LACV infectivity, pathogenesis, and immunogenicity in both weanling
mice and rhesus monkeys.
Results: Following intraperitoneal inoculation of mice, LACV replicated in various organs before
reaching the CNS where it replicates to high titer causing death from neurological disease. The
peripheral site where LACV replicates to highest titer is the nasal turbinates, and, presumably,
LACV can enter the CNS via the olfactory neurons from nasal olfactory epithelium. The mouse
infectious dose50 and lethal dose50 was similar for LACV administered either intranasally or
intraperitoneally. LACV was highly infectious for rhesus monkeys and infected 100% of the animals
at 10 PFU. However, the infection was asymptomatic, and the monkeys developed a strong
neutralizing antibody response.
Conclusion: In mice, LACV likely gains access to the CNS via the blood stream or via olfactory
neurons. The ability to efficiently infect mice intranasally raises the possibility that LACV might use
this route to infect its natural hosts. Rhesus monkeys are susceptible to LACV infection and
develop strong neutralizing antibody responses after inoculation with as little as 10 PFU. Mice and
rhesus monkeys are useful animal models for LACV vaccine immunologic testing although the
rhesus monkey model is not optimal.
Background
La Crosse virus (LACV), family Bunyaviridae, is a mos-
quito-borne pathogen endemic in the United States [1,2].
The LACV genome consists of three single-stranded, nega-
tive-sense RNA genome segments designated small (S),
medium (M), and large (L). The S segment encodes two
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proteins in overlapping reading frames: the nucleoprotein
(N) and a non-structural protein (NSS) which suppresses
type 1 interferon (IFN) in the mammal host. The M seg-
ment encodes a single polyprotein (M polyprotein) that is
post-translationally processed into two glycoproteins (GN
and GC), and a non-structural protein (NSM) [3]. GN and
GC are the major proteins to which neutralizing antibod-
ies are directed [4,5]. The L segment encodes a single open
reading frame for the RNA-dependent RNA polymerase
(L) [6].
The virus is transmitted by hardwood forest dwelling mos-
quitoes, Aedes triseriatus, which breed in tree holes and
outdoor containers. Ae. triseriatus feed on Eastern chip-
munks (Tamias striatus grinseus) and Eastern gray squirrels
(Sciurus carolinensis) which serve as amplifying hosts for
LACV [7-9]. Interestingly, the virus can be maintained in
the mosquito population in the absence of vertebrate
hosts by transovarial (vertical) transmission, thus allow-
ing the virus to over-winter in mosquito eggs [9]. More
recently, LACV has been isolated from naturally infected,
non-native Aedes albopictus mosquito [10]. The infection
of Ae. albopictus may represent a shift in virus ecology and
increases the possibility for generation of new reassortants
[11].
LACV was first identified as a human pathogen in 1960
after its isolation from a 4 year-old girl from Minnesota
who suffered meningoencephalitis and later died in La
Crosse, Wisconsin[12]. In humans, the majority of infec-
tions are mild and attributed to the "flu" or "summer
cold" with an estimated 300,000 infections annually, of
which there are only 70–130 serious cases reported
[1,2,13,14]. Isolation of virus is rare and has been made
from post-mortem brain tissue collected in 1960, 1978,
and 1993 [15-18]. Two isolates from non-fatal LACV cases
were collected in 1995, one from a brain biopsy of a child
and one from cerebrospinal fluid [16,19].
Histopathologic changes in two human cases, one from
1960 and one from 1978, were characteristic of viral
encephalitis. Inflammatory lesions consisted of infiltra-
tion of mononuclear leukocytes either diffusely or as
microglial nodules. The largest inflammatory foci were
observed in the cerebral cortex, including the frontal, pari-
etal, and temporal lobes, and foci could also be found in
the basal ganglion and pons. In these two cases, there was
a lack of inflammatory lesions in the posterior occipital
cortex, cerebral white matter, cerebellum, medulla, and
spinal cord [17]. Brain biopsy from a non-fatal LACV
infection contained areas of perivascular mononuclear
cuffing and focal aggregates of mononuclear and micro-
glia cells [16]. RT-PCR analysis of neural tissues from the
1978 case could only detect viral RNA in the cerebral cor-
tex and not in the medulla, cerebellum, spinal cord, basal
ganglion, or temporal lobe [20].
In children and adults, severe LACV encephalitis clinically
mimics herpes simplex virus encephalitis with fever, focal
signs, and possible progression to coma [16,21,22]. Con-
firmatory diagnosis has been made by RT-PCR of cerebro-
spinal fluid to exclude herpes simplex virus and by
fluorescent staining for LACV antigen in brain biopsy sec-
tions [16]. Children who recover from severe La Crosse
encephalitis may have significantly lower IQ scores than
expected and a high prevalence (60% of those tested) of
attention-deficit-hyperactivity disorder [13]. Seizure dis-
orders are also common in survivors [23]. Projected life-
long economic costs associated with neurologic sequelae
range from $48,775 – 3,090,398 per case [24]. Currently,
a vaccine or specific antiviral treatment is not available,
but could serve to reduce the clinical and economic
impact of this common infection.
Although evidence of LACV infection has been reported
for several species, only limited research has been done to
understand LACV pathogenesis in its natural host or
experimental rodents [8,25-27]. LACV administered sub-
cutaneously to suckling mice first replicates in muscle,
and viremia develops with virus invading the brain across
vascular endothelial cells [28-31]. Virus replication in
muscle was confirmed by immunohistochemical (IHC)
staining, and the predominant cell type infected in the
CNS is the neuron [28,32]. The virulence of LACV for mice
decreases with increasing age, similar to humans in which
it causes CNS disease predominantly in pediatric popula-
tions [13,28]. As an initial step in the establishment of
animal models useful for vaccine development for
humans, we sought to better characterize the tissue tro-
pism of LACV in mice by identifying the tissues that sup-
port LACV replication after peripheral inoculation. We
have previously described Swiss Webster mice as suitable
for characterization of LACV infection at birth and at 3-
weeks of age [6]. Here we inoculated 3-week old Swiss
Webster mice with either 1 or 100 LD50 of virus intraperi-
toneally. Twenty tissues were individually collected for six
consecutive days and processed for virus titration, immu-
nohistochemical staining, and histopathology studies.
Since experimental infection of non-human primates
with LACV has not been reported, we also sought to deter-
mine if rhesus monkeys were susceptible to LACV infec-
tion. Rhesus monkeys were chosen since they are
susceptible to a variety of neurotropic arboviruses, includ-
ing flaviviruses [33]. In this study, rhesus monkeys were
infected intramuscularly or subcutaneously with a mos-
quito or human isolate of LACV. These two isolates were
used since preliminary genomic sequence analysis indi-
cate that there are host specific differences between LACVVirology Journal 2008, 5:25 http://www.virologyj.com/content/5/1/25
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isolated from humans and mosquitos [6]. LACV was
found to be highly infectious for rhesus monkeys, but
infection did not result in viremia, disease, or significant
changes in blood chemistries or cell counts. However,
high titers of neutralizing antibodies developed in all
monkeys indicating that rhesus monkeys, although not
optimal, will be useful for studying the infectivity and
immunogenicity of LACV vaccine candidates.
Results
LACV replicates in various tissues after intraperitoneal 
inoculation of mice
Previous evaluation of LACV in suckling mice revealed
that it first replicated in striated muscle cells from which it
seeded the blood and next invaded the CNS, where it rep-
licated in neurons [28,32]. In developing a rodent model
for our live attenuated LACV vaccine development pro-
gram, we sought to characterize LACV infection in out-
bred weanling mice, rather than suckling mice, since older
mice can be used to study both the level of attenuation
and the immunogenicity of our LACV vaccine candidates.
To identify key steps in pathogenesis of LACV in weanling
mice, we evaluated LACV tissue tropism after peripheral
inoculation of wild-type virus and sought to identify tis-
sues in which virus replicated efficiently. Weanling Swiss
Webster mice (21–23 days-old) were inoculated intraperi-
toneally with 1 or 100 LD50 (2.5 or 4.5 log10 PFU) of
LACV/human/1960, and the tissues indicated in Figures 1
and 2 were collected from 3 mice per day on days 1–6 post
inoculation. Following inoculation of either dose, virus
could first be detected in tissue near the inoculation site
such as inguinal lymph nodes, spleen, and ovaries/uterus.
Virus was detected in serum on days 1–3, but rarely on
subsequent days even in moribund mice. By day three,
virus distribution was widespread and could be found in
the majority of tissues sampled, albeit at very low levels
with titers rarely exceeding those found in serum. The
highest virus titers detected were present in nasal tur-
binates, brain, and spinal cord. Respiratory tissue, includ-
ing lung and nasal turbinates, contained virus following
inoculation with 100 or 1 LD50 beginning on days 1 and
2, respectively. CNS infection appeared to follow respira-
Tissue distribution of La Crosse virus following intraperitoneal (IP) inoculation of Swiss Webster mice with 102.5 PFU Figure 1
Tissue distribution of La Crosse virus following intraperitoneal (IP) inoculation of Swiss Webster mice with 
102.5 PFU. aPercent of mice positive by plaque assay represented by shading: 100% black, 66% dark gray, 33% light gray, 0% no 
data entry. Mean virus titer calculated only for virus positive tissues. Areas left blank indicate virus titer below detection limit 
of 0.7 log10 PFU/tissue.
  Mean LACV titer (log10 PFU/g) on indicated day post inoculation
a
Tissue 1  2 3 4 5 6
Serum    2.5  3.0  2.7 
Inguinal lymph node  2.0  2.0      
Spleen   1.7  1.7     2.7 
Ovaries/uterus    1.7  2.7      
Pancreas  
Skin (stomach)    2.2      
Liver
Thymus  
Stomach  
Skin (front leg)             
Mesenteric lymph nodes     2.7      
Kidney       2.7   
Small intestine         1.0 
Large intestine             
Muscle     3.2     2.1 
Heart        4.3 
Lung    3.2  2.2      
Nasal turbinates     3.6    5.2  3.9 
Brain       5.1  5.8 
Spinal cord         3.0 Virology Journal 2008, 5:25 http://www.virologyj.com/content/5/1/25
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tory tissue infection, with virus being present in the brain
5 days after infection with 1 LD50 and on day 2 after infec-
tion with 100 LD50. At either virus dose, infection appears
early in the lymph nodes and major organs, with subse-
quent infection of the upper respiratory tract (nasal tur-
binates) followed by infection of the brain and eventually
the spinal cord. By day six, mice began to succumb to
infection in the high dose group showing signs of paraly-
sis whereas mice in the low dose group failed to show clin-
ical signs at this time, but would have succumbed later in
infection. These results indicate that LACV replicates to
low to moderate levels in peripheral tissues in weanling
mice, with the nasal turbinates rather than striated muscle
being the major site of replication.
Intranasal infection of mice with LACV
Since LACV replicated to high titers in the nasal tur-
binates, we sought to determine if intranasal inoculation
of mice with LACV could lead to infection. Three-week-
old Swiss Webster weanling mice (n = 6/dose) were inoc-
ulated intranasally (IN) (10 µl volume) or intraperito-
neally (IP) (100 µl volume) with serial dilutions of LACV/
human/1960, and the LD50  and 50% infectious dose
(ID50) were determined. Clinical disease served as a surro-
gate for lethality and mice were promptly euthanized
prior to succumbing to LACV disease. In both groups,
clinical disease was first noted on day 6 (Figure 3). Twenty
days post-inoculation, the LD50 was determined. All sur-
viving mice were tested for the development of a neutral-
izing antibody response. To determine the ID50 titer, mice
were considered infected if they either developed clinical
disease or a serum neutralizing antibody titer. The LD50
was similar in both the IN and IP groups (2.4 and 2.3
log10 PFU, respectively) with the LD50 following IP injec-
tion in agreement with previous experiments [6]. The ID50
titers (1.5 and 1.6 log10 PFU for the IN and IP routes,
Tissue distribution of La Crosse virus following intraperitoneal (IP) inoculation of Swiss Webster mice with 104.5 PFU Figure 2
Tissue distribution of La Crosse virus following intraperitoneal (IP) inoculation of Swiss Webster mice with 
104.5 PFU. aPercent of mice positive by plaque assay represented by shading: 100% black, 66% dark gray, 33% light gray, 0% no 
data entry. Mean virus titer calculated only for virus positive tissues. Areas left blank indicate virus titer below detection limit 
of 0.7 log10 PFU/tissue. bTissue samples collected from one moribund mouse.
  Mean LACV titer (log10 PFU/g) on indicated day post inoculation
a
Tissue 1  2 3 4 5 6
b
Serum  2.7  2.8  2.8   
Inguinal lymph node  1.7  1.7  2.2     
Spleen 2.0    3.1     
Ovaries/uterus  2.4  1.7  3.0     2 
Pancreas  3.9  2.6  2.7     
Skin stomach  2.0  1.4      
Liver   3.6      
Thymus       
Stomach  
Skin front leg     1.7     
Mesenteric lymph nodes     3.2     
Kidney     2.4     
Small intestine     1.9    3.3   
Large intestine       3.2   
Muscle     3.2  2.4  3.0  2.1 
Heart    2.0  2.7  4.3   
Lung  2.8  2.9  3.8    3.8  3.8 
Nasal turbinates    3.6  4.4  4.0  5.6  7.3 
Brain    1.8  2.9  7.4  7.6  6.9 
Spinal cord     3.5  5.6  7.2  6.4 Virology Journal 2008, 5:25 http://www.virologyj.com/content/5/1/25
Page 5 of 15
(page number not for citation purposes)
respectively) were slightly lower than the LD50 titers, indi-
cating LACV can cause a subclincal infection in weanling
mice, but only at low doses.
Histopathology and Immunopathology in mice infected 
with LACV 100 LD50
To further characterize the LACV infection in weanling
mice, an additional group was inoculated intraperito-
neally with 100 LD50 of LACV/human/1960 and selected
tissues (serum, muscle, nasal turbinate, brain, and spinal
cord) were collected for virus quantitation (n = 5, daily for
six days) to confirm titers found in Figure 2 and for his-
topathological and immunohistochemical (IHC) exami-
nation (n = 3, daily for six days), and the data is
summarized in Table 1 and Figures 4 and 5. Virus titers for
nasal turbinates, brain, spinal cord, muscle, and serum
were in agreement with findings in Figure 2 (data not
shown). Histopathologic lesions in the brain (including
areas of the olfactory bulb, cerebral cortex, thalamus, hip-
pocampus, and medulla oblongata) and spinal cord
included perivascular cuffing (Figure 4A), neuronal
degeneration (Figure 4B–C), necrosis (either single cell or
small foci), and apoptosis (4F). There was an infiltration
of CD3+ lymphocytes and macrophages (Figure 4D–E).
The most extensive lesions occurred in the medulla oblon-
gata and were associated with perivascular cuffing.
Histopathological changes were minimal outside the
CNS. In the spleen, lymphoid atrophy was only observed
on days 3–4 post-infection. Plasmacytosis in the spleen
was observed on days 4–6 and areas of necrosis were
observed on days 4–5 with myeloid hyperplasia on day 5.
Histopathological changes were not observed in respira-
tory nasal epithelium or muscles of the upper rear limb.
To determine the location of cells expressing viral antigen,
tissues were immunostained for La Crosse virus antigens.
Viral antigens were not observed in the nasal turbinates,
muscle, spleen, or pancreas. However, viral antigen was
detected in the olfactory bulb of the brain, thalamus, cer-
ebrum, medulla oblongata, and spinal cord.
On day 5, viral antigen could be detected in all sampled
brain regions with a greater number of cells and regions
positive for viral antigen than for overt histologic lesions.
Mild perivascular cuffing was seen in a few areas and sin-
gle cell necrosis was seen in areas stained positive for viral
antigen. At this time and at later days, the olfactory bulb
was more extensively involved (Figure 5A), although viral
antigen was not detected in sections of the underlying
nasal epithelium. Viral antigen could be detected in the
brain tissues of all mice on day 5, but only small foci of
antigen were seen in the spinal cord of one mouse suggest-
ing brain infection proceeds spinal cord infection.
By day 6, viral infection in the CNS was widespread and
extensive throughout all regions of the brain and spinal
cord (Figure 5B). Neurons were the main cell expressing
viral antigens, but supporting glia also appeared positive
(Figures 5D–F). Single cell necrosis, focal necrosis (more
than one cell), and apoptotic bodies were prominent
throughout the lesions (Figure 4C) and apoptotic bodies
stained positive by TUNEL staining (Figure 4F). Degener-
ative neuronal changes were also commonly seen, includ-
LACV is highly virulent in mice inoculated by either the intraperitoneal (IP) or intranasal (IN) route Figure 3
LACV is highly virulent in mice inoculated by either the intraperitoneal (IP) or intranasal (IN) route. Percent 
survival for LACV/human/1960 after IP (left) or IN (right) inoculation routes. Changes in percent survival did not occur after 
day 10.
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Histopathologic changes on day 6 in the CNS of LACV infected mice Figure 4
Histopathologic changes on day 6 in the CNS of LACV infected mice. (A) Perivascular cuffs and gliosis in the thala-
mus. H&E X400. (B) Neurons of the cervical spinal cord with degenerative changes of pale cytoplasm and vacuoles (arrows). 
H&E X1000. (C) Thalamus with apoptotic cells (arrows) and degenerative neurons (with swollen vacuolated nuclei). H&E 
X1000. (D) CD3+ lymphocytes in the meninges and blood vessels in the thalamus. Immunohistochemistry, hematoxylin coun-
terstain, X200. (E) Macrophages (MAC-2 +) in perivascular cuffs and areas of gliosis in the hippocampus. Immunohistochemis-
try, hematoxylin counterstain X200.(F) TUNEL positive (brown) apoptotic bodies in the thalamus. Immunohistochemistry, 
hematoxylin counterstain X1000.Virology Journal 2008, 5:25 http://www.virologyj.com/content/5/1/25
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Viral antigen is detected in the CNS of LACV infected mice Figure 5
Viral antigen is detected in the CNS of LACV infected mice. (A) LACV antigen-positive cells in the mitral cell layer 
(arrow) and granule cell layer (arrowhead) of the main olfactory bulb. Abbreviations: AL-airway lumen, OE-olfactory epithe-
lium, LP-lamina propria, TB-turbinate bone, ONL-olfactory nerve layer, GL-glomerular layer, EPL- external plexiform layer, M-
mitral cell layer, GR-granule cell layer. Day 6, X100. (B) Low magnification of a coronal section of mouse brain showing abun-
dant La Crosse viral antigen. Abbreviations: C-cerebral cortex, CAM-cornu ammonis of hippocampus, DG-dentate gyrus, 
HPA-posterior hypothalamic area, MP-premamillary nucleus, PAG-periaqueductal gray, PT-pretectum, R-reticular nucleus of 
thalamus, ZI- zona inserta. Day 6, X12.5. (C) Cervical spinal cord cross section showing abundant La Crosse viral antigen in 
grey matter. Abbreviations: GC-gray commissure, DH-dorsal horn, LH-lateral horn, VH-ventral horn. Day 6, X100. (D) Viral 
antigen in a punctate pattern in neurons (arrows) in the locus coeruleus. Day 5, X400. (E) Medulla oblongata with abundant 
LACV antigen in many neurons (arrow heads) with associated perivascular lymphocyte cuffing (indicated with arrows). Day 4, 
X200. (F) La Crosse viral antigen in the cytoplasm of medullary neurons (arrows). Day 6, X1000. All images immunohisto-
chemistry, hematoxylin counterstain.
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿Virology Journal 2008, 5:25 http://www.virologyj.com/content/5/1/25
Page 8 of 15
(page number not for citation purposes)
ing nuclear vacuolization and cell shrinkage (Figure 4B–
C). To identify cell infiltrates in a moribund mouse, brain
sections were immunostained using anti-CD3 or anti-
macrophage antigen-2 (MAC-2) antibodies. CD3+ cells
and macrophages were seen in perivascular locations and
in areas of the neuronal lesions (Figure 4D–E). Within the
grey matter of the spinal cord, there were small perivascu-
lar cuffs of lymphocytes and degenerative neurons with
viral antigen expressed in numerous neurons (Figure 4B,
5C). On day 6, 2 of 3 of the mice had abundant viral anti-
gen in the cervical and thoracic regions of the spinal cord,
and only one mouse had viral antigen in the lumbar spi-
nal cord supporting the observation the infection travels
caudally from the brain down the spinal cord.
Inoculation of rhesus monkeys with LACV
To develop a non-human primate model of LACV infec-
tion for pathogenesis studies and for testing of future vac-
cine candidates, rhesus monkeys were inoculated with 105
PFU of biologically cloned (terminally diluted) human or
mosquito LACV (LACV/human/1978-clone, LACV/mos-
quito/1978-clone). Illness was not observed following
virus administration, and virus was not detected at any
time in serum samples (Table 2). Virus was present at a
low titer in lymph nodes on days 6, 8, and 12, however,
virus replication in these tissues could not be identified by
IHC staining. Despite the low level (or absence) of
viremias and highly restricted replication in the tissues
sampled, all monkeys developed neutralizing antibody
responses that were first detected on days 6–8 indicating
that the each monkey was infected. Twenty-eight days
after inoculation, neutralizing antibody titers (PRNT60)
for each group were in the range of 1:560 – 1:2186 (Table
2). Low-level cross-reactive antibodies were present in two
monkeys (CL6E and DBOH) at the start of the experi-
ment. A boost in antibody titer in these monkeys was not
observed compared to other monkeys, suggesting that this
experimental LACV infection was a primary infection.
Complete blood counts (CBC) with differential and
blood chemistries were analyzed at each blood collection.
Since LACV infection in monkeys was asymptomatic and
also since differences between the four virus groups indi-
cated in Table 2 were not observed, the CBC and blood
chemistry data were averaged for the 16 animals to detect
changes in blood values during the course of infection
(Table 3). Days in which specific parameter values for a
significant number of monkeys were greater than 1 stand-
ard deviation from normal appear boxed in Table 3 with
mean values for each test shown. After day 6, the majority
of monkeys experienced a slight anemia, which may in
part be associated with the overnight fast in preparation
for anesthesia prior to each blood collection. This analysis
suggests that infection of major organs such as liver was
minimal or absent.
To estimate the minimum dose required to infect a mon-
key, rhesus monkeys were inoculated with LACV/mos-
quito/1978-cl at 101 or 103 PFU subcutaneously. Blood
was collected on days 0, 21, 28, and 42, and serum neu-
tralizing antibody titers were determined. Mean neutraliz-
ing antibody titers were 1:355 and 1:82 for the 101 or 103
PFU dose groups, respectively, and all monkeys serocon-
verted by day 28 (PRNT60 ≥ 40) (Table 4). Thus, LACV is
highly infectious for rhesus monkeys even at a dose of 101
PFU and results in the induction of a high level of neutral-
izing antibody. However, LACV infection did not result in
identifiable clinical abnormalities in this group of 24
monkeys.
Table 1: Spread of virus from brain to spinal cord after IP inoculation with 104.5 PFU LACV/human/1960.
No. of mice with detectable viral antigen or histopathologic lesionsa
Brain Spinal cord
Olfactory bulb Thalamus Cerebral cortex Medulla Cerebellum Cervical Thoracic Lumbar
Day IHCb HEc IHC HE IHC HE IHC HE IHC HE IHC HE IHC HE IHC HE
1 0 0 00 0 0 00 0 0 000000
2 0 0 00 0 0 00 0 0 000000
3 0 0 00 0 0 00 0 0 000000
4 1 1 11 1 0 11 0 0 000000
5 3 0 31 2 0 10 1 0 111111
6 3 2 33 3 2 32 1 0 222110
a Data displayed as total positive by IHC and HE (n = 3). Viral antigen or lesions were not observed in nasal turbinates, muscle, spleen, or pancreas. 
Tissues from three control mice were collected on days 1 and 6 and processed for HE and IHC comparisons, viral antigen or lesions were not 
present.
b Immunohistochemical stain
c Hemotoxylin and eosin stainVirology Journal 2008, 5:25 http://www.virologyj.com/content/5/1/25
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Discussion
As an initial step in development of a live attenuated
LACV vaccine, we sought to better characterize LACV
infection in weanling mice because at this age mice can be
used to evaluate both the level of attenuation and immu-
nogenicity of candidate vaccine viruses. Previous LACV
pathogenesis studies in suckling mice inoculated subcuta-
neously with a mosquito isolate of LACV demonstrated
that viral antigen was detected in the cytoplasm of striated
muscles, the interscapular brown fat, and the endothelial
and smooth muscle cells of small arteries and veins [28].
When virus was first detected in the brain, it was confined
to cerebral vascular endothelial cells but later spread to
neurons. The authors suggest that the late infection of the
dorsal route ganglion indicates that the virus does not
penetrate the CNS via nerves but rather by vascular
endothelial cells [28]. This previous model therefore sug-
gests that virus first replicates in muscle cells leading to the
development of viremia with subsequent hematogenous
spread to the CNS, and we sought in the present study to
examine if this pattern of infection also occurred in wean-
ling mice.
Table 2: LACV is immunogenic in rhesus monkeys and can be detected in the lymph nodes.
Homologous neutralizing antibody titer on indicated day (reciprocal PRNT60)c
Virus and 
inoculation 
route
Monkey # Temp. 
(°F)a
Lymph 
node virus 
titersb
- 7024681 01 2 1 4 2 1 2 8 G M T d 
(Day 28)
Human/
1978/clone 
(SQ)
DB00 2.3 (day 
12)
<5 <5 <5 <5 <5 13 22 166 620 1465 2924 2186
DB1Z <5 <5 <5 <5 <5 24 137 126 332 679 1412
CL74 <5 <5 <5 <5 <5 <5 31 199 546 1370 1374
DBCV <5 <5 <5 <5 <5 6 43 246 234 1684 4022
Human/
1978/clone 
(IM)
DB9J <5 <5 <5 <5 <5 <5 66 343 1011 603 1776 1906
DB5C 1.4 (day 
12)
<5 <5 <5 <5 <5 <5 74 282 2382 7451 2714
DB7Y 103.2 (day 
8)
<5 <5 <5 <5 <5 <5 15 37 230 4041 1628
DB3W 102.8 (day 
6)
<5 <5 <5 <5 <5 <5 40 1643 460 2633 1688
Mosquito/
1978/clone 
(SQ)
DB70 <5 <5 <5 <5 37 25 90 623 672 2325 3008 560
DB8N 0.7 (day 
12)
<5 <5 <5 <5 12 29 72 194 161 211 663
CK74 <5 <5 <5 <5 <5 14 38 250 434 1023 399
CL2G <5 <5 <5 <5 7 7 8 19 14 120 124
Mosquito/
1978/clone 
(IM)
DBCZ <5 <5 <5 <5 12 38 834 1325 3050 3695 4493 1691
CL6E 103.1 (day 
6)
0.7 (day 6) 5 6 6 <5 16 39 180 1960 2809 3875 960
DB0H 13 13 18 13 15 28 130 516 1566 1134 687
DA9F 102.9 (day 
-7)
0.7 (day 8) <5 <5 <5 <5 <5 11 94 1833 3189 3656 2762
a Rectal temperature collected at time of blood draw. Temperatures outside the normal range (98–102.7 F) indicated by day in parenthesis, normal 
values left blank.
b Lymph nodes were collected on days 4, 6, 8, and 12 for virus titer and IHC staining. Viral titers are expressed as log10 PFU/half lymph node (day 
post inoculation). Viral antigen was not observed using IHC staining. Blank spaces indicate that virus was not detected in the lymph nodes. Lower 
limit of detection was .7 log10 PFU/tissue.
c Limit of detection for neutralizing antibodies is 1:5 dilution.
d Geometric mean neutralizing antibody titer.Virology Journal 2008, 5:25 http://www.virologyj.com/content/5/1/25
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In weanling mice inoculated intraperitoneally with 1 or
100 LD50 of LACV, virus was first detected on days 1 – 3 in
tissues near the inoculation site. At either dose, virus was
no longer detectable by days 4 and 5 in these tissues, sug-
gesting that it was rapidly cleared by the innate immune
system. Interestingly, the virus was not detected in muscle
tissue until day 3 post inoculation and clearly did not
preferentially infect this tissue. Rather, outside the CNS,
the virus replicated to highest titers in the nasal turbinates
and appears to spread from this site into the brain. Immu-
nohistochemical staining of the nasal turbinate tissue was
not sensitive enough to identify the LACV infected cells,
but is thought LACV may gain access to the CNS via cells
in the nasal turbinates. This suggestion is offered with the
caveat that respiratory epithelial cells could also have
been infected, but the magnitude of the infection could
not be detected with the IHC staining. To travel from the
nasal olfactory epithelium to the olfactory bulb, the virus
Table 3: Infection of rhesus monkeys with LACV results in limited changes in blood chemistries or cell counts.
Mean test value on indicated day post inoculationa
Testb Unit Mean ± SDc 2468 1 0 1 2 1 4 2 1 2 8
CBC
White blood count THSN/UL 9.7 ± 2.9 7.9 9.2 9.2 8.3 8.2 8.5 8.0 6.7 7.2
Red blood count MILL/UL 5.7 ± 0.3 5.5 5.4 5.3 4.8 5.0 5.2 5.2 5.4 5.1
Hemoglobin GM/DL 12.8 ± 0.5 12.7 12.3 11.9 11.0 11.5 11.6 11.4 12.1 11.8
Hematocrit Percent 38.9 ± 1.7 38.7 37.7 36.8 33.8 35.8 35.8 35.8 38.2 37.1
MCV FL 68.5 ± 2.7 71 70.4 68.9 68.1 71.1 68.6 69.9 70.2 72.2
MCH PICO GM 22.5 ± 0.8 23.3 23.0 22.4 22.4 22.8 22.2 22.0 22.2 23.0
MCHC Percent 32.9 ± 0.8 32.9 32.7 32.5 32.7 32.0 32.4 31.4 31.7 31.9
Platelet THSN/UL 391.7 ± 83.6 419.4 371.3 348.2 395.3 449.9 432.2 431.4 445.2 389.5
Differential
Absolute polys THSN/UL 3550.7 ± 1779.4 2057.5 4299.9 3888.3 4243.2 3539.1 3649.1 2758.6 2291.6 2510.0
B a n d s T H S N / U L 0  ±  0 000000000
Lymphocytes THSN/UL 5301.9 ± 1830.4 5142.9 4347.6 4773.3 3727.5 4054.3 4300.8 4187.0 3817.5 3803.4
Monocytes THSN/UL 342.9 ± 148.0 362.1 351.6 365.4 297.1 341.0 277.2 272.0 253.8 241.5
Eosinophils THSN/UL 257.6 ± 181.1 209.8 200.8 230.0 167.9 290.6 235.9 213.7 229.6 180.8
Basophiles THSN/UL 0 ± 0 0 0 0 8.1 0 0 0 13.8 0
Chemistry
Sodium MEQ/L 152.2 ± 3.5 152.2 152.2 152.2 152.2 152.2 152.2 152.2 152.2 152.2
Potassium MEQ/L 3.9 ± 0.5 4.2 3.9 3.8 3.6 4.1 3.8 4.1 4.2 3.8
Chloride MEQ/L 110.6 ± 3.5 110.6 110.2 109.1 108.1 110.4 105.0 107.1 110.3 106.7
Calcium total MG/DL 9.7 ± 0.3 9.5 9.5 9.3 9.0 9.4 9.6 9.4 9.6 9.8
Phosphorus MG/DL 5.9 ± 1.0 5.9 5.8 5.4 5.6 5.9 5.8 5.6 5.8 6.7
Magnesium MEQ/L 1.7 ± 0.2 1.8 1.7 1.6 1.7 1.8 1.6 1.6 1.6 1.8
AST (SGOT) U/L 38.5 ± 7.4 39.1 43.7 46.8 41.3 43.2 48.4 39.6 36.4 55.0
ALT (SGPT) U/L 29.4 ± 9.5 31.2 34.1 35.9 36.4 34.8 34.8 33.0 26.5 30.9
ALP U/L 692.0 ± 166.2 604.5 586.1 597.0 597.8 510.1 532.6 548.5 529.4 553.5
Amylase U/L 203.0 ± 56.0 231.5 219.3 211.1 203.2 221.8 228.8 216.5 206.3 215.6
Glucose MG/DL 65.0 ± 11.3 76.9 88.6 116.7 132.8 70.4 66.8 65.4 64.8 66.8
BUN MG/DL 20.0 ± 7.5 18.5 19.2 16.6 18.1 22.9 18.9 18.7 16.3 22.0
Creatinine MG/DL 0.8 ± 0.2 0.7 0.8 0.7 0.8 0.7 0.7 1.2 0.8 0.8
Cholesterol MG/DL 153.8 ± 31.4 157.1 153.6 139.8 142.3 158.6 150.3 148.6 146.3 151.6
Triglyceride MG/DL 65.3 ± 21.7 47.1 59.9 75.4 49.5 37.7 61.1 70.5 58.7 60.8
Bilirubin, total MG/DL 0.2 ± 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.2
Albumin G/DL 4.5 ± 0.2 4.5 4.5 4.2 4.2 4.4 4.3 4.2 4.3 4.6
Protein, total G/DL 6.9 ± 0.3 6.9 6.9 6.5 6.5 6.9 6.6 6.6 6.8 7.2
Globulin G/DL 2.4 ± 0.2 2.4 2.4 2.3 2.4 2.5 2.4 2.4 2.6 2.6
Lipase-PS U/L 32.4 ± 27.6 30.4 27.7 53.1 25.4 32.2 38.4 39.5 33.1 28.7
Osmolality, Calculated mOsm/kg 306.0 ± 55.1 298.1 300.1 299.6 292.6 297.1 286.8 288.1 296.3 288.9
aDays with significant number of monkeys 1 SD from the pre-inoculation mean (day -7 and 0 combined) are boxed (chi square, p < 0.05, n = 16), 
mean values displayed.
bAbbreviations: MCV-mean corpuscular volume, MCH-mean corpuscular hemoglobin, MCHC-mean corpuscular hemoglobin concentrations, AST-
aspartate aminotransferase, ALT-alanine aminotransferase, ALP-alkaline phosphatase, BUN-blood urea nitrogen.
cPre-inoculation mean determined from samples collected on days -7 and 0 post inoculation.Virology Journal 2008, 5:25 http://www.virologyj.com/content/5/1/25
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would follow olfactory neurons into the brain, as infec-
tion is first detected in the rostral section of the brain.
Although virus replication in nasal turbinate tissue was
detected, we were unable to identify the cells that were
infected. Viruses such as vesicular stomatitis virus, rabies
virus, mouse hepatitis virus, Borna disease virus, pseudor-
abies virus, and herpes simplex virus have all been dem-
onstrated to enter the mouse CNS via olfactory neurons
[34-40]. It is important to note that 2 of 62 mice tested
had detectable virus within the brain without detectable
virus in the nasal cavity (individual data not shown) sug-
gesting that more than one route might be used to gain
access to the CNS. We were surprised by the ability of the
virus to infect intranasally, and found that the LD50 and
ID50 were almost identical by either route by of inocula-
tion. The kinetics of the development of clinical disease
that occurred following intranasal administration of virus
was similar for virus given IP or IN.
The finding that LACV is able to infect very efficiently via
the nasal route has possible implications for the ecology
of the virus. It is possible that infectious virus is present in
water collections containing Aedes mosquito larvae, e.g.,
tree holes, since the virus has been shown to be transmit-
ted from infected mosquitoes to larvae via eggs. A mam-
malian host that drinks the water would intake both fluid,
which might contain free virus from lysed larvae, and
infected larvae, either of which could initiate an infection
in the mammalian host. Thus, exposure to such water
could lead to an alternate route of infection for the natural
hosts, i.e., the oral/nasal route in addition to the vector-
bourne route. This hypothesis needs to be confirmed
experimentally but remains an interesting possibility.
In the CNS of the weanling mouse, LACV infects predom-
inantly neurons (some microglial cells are also infected)
with spread in a rostral to caudal direction eventually
reaching the lumbar spinal region. In both mice and
humans, virus has been detected in the cerebral cortex,
however infection appears more widespread in the mouse
CNS with virus detection in the medulla oblongata, cere-
bellum, thalamus, olfactory bulb, and all regions of the
spinal cord. The virus used in this study, LACV/human/
1960, was isolated and passaged twice in C6/36 mosquito
cells and was not previously adapted to growth in mouse
neural tissue. One surprising difference between human
and mouse infection was the detection of virus replication
by IHC and the development of lesions in the mouse spi-
nal cord [17].
Taken together, these data suggest that in weanling mice
the virus first replicates in the periphery near the inocula-
tion site. If the infection is not quickly controlled, the
virus disseminates, most likely via blood, to the nasal tur-
binates. The detection of virus and lesions first in the ros-
tral brain suggest the virus may utilize olfactory neurons
to gain access to the CNS. The differences in findings
between our study and previous work may be the result of
differences in virus strain (mosquito vs. neurovirulent
human isolates), mouse strain (outbred white vs. Swiss
Webster), mouse age (suckling vs. weanling), inoculation
route (subcutaneous vs. intraperitoneal) and dose (1000
TCID50 vs. 1 or 100 LD50). Although sequence data is not
available for the strain used in the previous mouse patho-
genesis work, it is known that the virus was a mosquito
isolate and not directly linked to human disease [28].
In humans the majority of infections are asymptomatic,
but children hospitalized with severe disease present with
fever (86%), headache (83%), vomiting (70%), disorien-
Table 4: LACV/mosquito/1978 is highly infectious in rhesus monkeys following subcutaneous inoculation.
Homologous neutralizing antibody titer on indicated day (reciprocal PRNT60)a
Dose PFU (SQ) Monkey # 0 21 28 42
103 DB5C <10 1131 156 41
103 DBNF <10 1236 420 230
103 DBFD <10 151 157 128
103 DBNL <10 25 49 37
GMT: <10 270 150 82
101 DBPJ <10 1175 783 300
101 DBKL <10 1529 831 755
101 DBTB <10 150 282 503
101 DBKA <10 2616 448 140
GMT: <10 916 535 355
aLimit of detection for neutralizing antibodies is 1:10 dilutionVirology Journal 2008, 5:25 http://www.virologyj.com/content/5/1/25
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tation (42%), seizures (46%) and elevated peripheral
white-cell counts (49%) [13]. Like the majority of human
infections, rhesus monkeys in the current study experi-
enced a subclinical infection without the development of
systemic disease or neurologic symptoms. A much greater
number of monkeys would probably need to be tested to
detect neurologic symptoms after peripheral inoculation.
Nevertheless, all monkeys were infected with LACV and
developed neutralizing antibody responses, even after
inoculation with as little as 10 PFU. Future work will
include the intracerebral inoculation of rhesus monkeys
to determine if LACV is neurovirulent in this species, but
this will wait until vaccine candidates have been identi-
fied.
It is still unclear why so many human LACV infections
remain asymptomatic. In our mouse model, infection
with 1 LD50 of virus resulted in delayed CNS infection
compared to mice receiving 100 LD50. Mice were able to
control virus infection at doses at or below the LD50, and
developed strong neutralizing antibody responses. The
LACV ID50 for humans is unknown, but if human expo-
sure is limited to a small dose, the virus may be effectively
controlled by the immune system and CNS infection may
be averted. If, like our mouse model, an individual is
exposed to a greater dose of virus, virus growth may out-
pace control mechanisms leading to CNS infection. To
further support the role of immune control affecting
human disease outcome, it has been shown that individ-
uals residing in endemic areas with major histocompati-
bility complex molecule B49 on CD8+ cytotoxic T
lymphocytes (HLA-B49) had a greater relative risk of
developing encephalitis after infection (relative risk
17.65, χ2 = 7.3, P < 0.1). Infected individuals with HLA-
DR5 had a lower relative risk of developing seizures (rela-
tive risk 0.22, χ2 = 5.10, P < 0.025) [41].
Conclusion
In weanling Swiss Webster mice, the LD50 and ID50 are
similar, indicating that most infections lead to a lethal
outcome at this age. LACV first replicates in tissues near
the inoculation site, enters the blood stream, infects the
nasal turbinates, and gains access to the CNS, presumably
via olfactory neurons. This model will be useful to identify
attenuated vaccine candidates that are deficient in the
ability to disseminate from the site of inoculation, to rep-
licate to high titers in the nasal turbinates, or to establish
infection in mouse CNS. The CNS infection of mice
appears more widespread than described for human infec-
tion, both in the brain and spinal cord. LACV is highly
infectious both by the IP and IN routes suggesting that
infection of natural mammalian hosts such as the chip-
munk or squirrel might occur by the oral/intranasal route
in addition to the bite of an infected mosquito. In rhesus
monkeys, LACV is highly infectious with as little as 10
PFU resulting in the development of neutralizing antibod-
ies, but clinical disease is not observed at any dose tested,
suggesting that rhesus monkeys will be useful for studying
the infectivity and immunogenicity of live attenuated
virus vaccine candidates, but will be of limited usefulness
for the evaluation of their level of attenuation.
Methods
Cells and viruses
C6/36 cells (Aedes albopictus mosquito larvae) were main-
tained in Earle's MEM supplemented with 10% fetal
bovine serum (HyClone), 2 mM L-glutamine (Invitro-
gen), and 1 mM non-essential amino acids. Vero cells
(African green monkey kidney) were maintained in Opti-
PRO™SFM medium (Invitrogen) supplemented with 4
mM L-glutamine (Invitrogen).
LACV/human/1960 was isolated from post-mortem brain
tissue collected from a Minnesota patient hospitalized in
La Crosse, Wisconsin and passaged two times in C6/36
cells. LACV/mosquito/1978 was isolated from mosqui-
toes collected in North Carolina and passaged once in
mouse brain and three times in Vero cells. LACV/human/
1978 was isolated from post-mortem brain tissue col-
lected in Wisconsin and passaged once in mouse brain,
twice in BHK-21 cells, and once in Vero cells. Biological
clones were generated by terminal dilution in Vero cell
cultures. Passage histories and complete genomic
sequences for all stocks used in this paper have been pre-
viously published (EF485030-EF48538) [6].
Determination of intranasal and intraperitoneal infectious 
dose of LACV
Weanling Swiss Webster mice (Taconic Farms, German-
town, NY) were inoculated with LACV/human/1960
diluted in L15 media (Invitrogen) intraperitoneally (100
µl volume) or intranasally (10 µl volume) while under
isofluorane anesthesia. Mice were observed daily for 20
days for clinical disease including tremors, seizures, and
limb paralysis. Moribund mice were promptly eutha-
nized. Serum was collected 20 days after inoculation for
determination of the presence and titer of neutralizing
antibodies.
LACV tissue distribution in mice
The replication of LACV virus was evaluated in 3-week-old
weanling female Swiss Webster mice (Taconic Farms, Ger-
mantown, NY). All animal experiments were carried out
in accordance with the regulations and guidelines of the
National Institutes of Health. The Swiss Webster mice,
were inoculated IP with 1 or 100 LD50 in a volume of 100
µl [6]. The tissues indicated in Table 1 were collected indi-
vidually (3 mice per day for 6 days at each dose of virus),
weighed, homogenized in L15 with SPG buffer (final con-
centration 218 mM sucrose, 6 mM L-glutamic acid, 3.8Virology Journal 2008, 5:25 http://www.virologyj.com/content/5/1/25
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mM dibasic potassium phosphate, pH 7.2). Homogenates
were centrifuged for 10 minutes at 3000 rpm to remove
cell debris and aliquots were frozen at -80°C until virus
quantitation was performed. All mice were carefully
observed twice daily for clinical disease including tremors
and limb paralysis. Mice exhibiting clinical disease were
promptly euthanized.
Quantitation of virus in tissues
Monolayer cultures of Vero cells grown on 24-well plates
were infected in duplicate with ten-fold serial dilutions of
tissue homogenate, and the cells were overlayed with
OptiMEM (Invitrogen) supplemented with 1% methylcel-
lulose, 5% FBS, 2.5 µg/ml amphotericin B, and 20 µg/ml
ciprofloxicin. Five days after infection the overlay was
removed and cells were washed twice with PBS. The cells
were fixed and stained for 10 minutes with crystal violet
solution, virus plaques were enumerated, and tissue titers
were expressed as mean log10 PFU/g tissue.
Histopathology and immunohistochemical (IHC) staining
Weanling Swiss Webster mice were inoculated intraperito-
neally with 100 LD50 of LACV/human/1960, and tissues
were collected for six consecutive days for virus titration
(n = 5) and pathology (n = 3) per day. Virus titrations were
performed to confirm previous virus kinetics. Tissues col-
lected for pathology were fixed in 10% neutral buffered
formalin (NBF) for a minimum of 72 hours, embedded in
paraffin and sections were prepared at 4–5 (µm). When
bone was present in the tissue, as with muscle, nasal cav-
ity, and spinal cord, tissues were decalcified using Immu-
nocal (Decal Chemical Corp. Tallman, NY). Sections were
stained with hematoxylin and eosin (H&E). A serial sec-
tion was saved for immunohistochemical staining (see
below).
For immunohistochemical analysis, fixed serial sections
of mouse tissues were mounted onto slides and deparaffi-
nized with xylene, rehydrated in a series of ethanol solu-
tions (100%, 95%, 70%, 50%), and washed with
deionized water. The sections were first treated with per-
oxidase blocking solution [2% H2O2(30%), 80% metha-
nol, 18% dH2O] at room temperature for 5 minutes to
quench endogenous peroxidases. Sections were pretreated
with Pro K enzyme (Dako Corp., Carpinteria CA) at room
temperature for 10 minutes and stained using the Mouse
on Mouse Polymer detection system (Biocare Medical,
Concord, CA). The primary antibody, mouse anti-La
Crosse virus monoclonal antibody #18752 (QED Bio-
science INC, San Diego, CA), recognized the G2 (Gn)
glycoprotein and was used at a dilution of 1:200.
TUNEL Staining to detect apoptosis was preformed using
the "DeadEnd™ Colorimetric TUNEL System" (Promega
USA, Madison, WI). Sections were pretreated with Pro K
enzyme (provided in the kit, diluted 1:500 with PBS).
Strepavidin (also provided in the kit) was diluted at 1:500
in PBS.
To detect CD3+cells, slides were steam hydrated and pre-
treated with Diva Solution (Biocare Medical Concord,
CA) for 20 minutes. The primary antibody, rabbit anti-
human CD3, (A-0452, Dako Corporation, Carpentaria,
CA) was used at a dilution of 1:300. The detection system
was the Standard ABC kit (Vector Laboratories, Burlin-
game, CA), with 3,3'-diaminobenzidine (DAB) as the
chromogen and a modified Harris hematoxylin counter-
stain.
To detect macrophage antigen 2 (MAC-2) expressing cells,
slides were stream hydrated with citrate buffer for 20 min-
utes. The primary antibody, rat anti-Mac-2 (TIB-166,
ATCC, Mannasas, VA) was used at a 1:200 dilution fol-
lowed by a biotinylated goat-anti-rat IgG secondary anti-
body and developed with Streptavidin HRP (Biocare,
Concord, CA).
Inoculation of rhesus monkeys
Rhesus monkeys were inoculated with 105 PFU of biolog-
ically cloned human or mosquito LACV (LACV/human/
1978-clone, LACV/mosquito/1978-clone). Each virus was
inoculated intramuscularly (n = 4) or subcutaneously (n
= 4). Blood samples were collected on days -7, 0, 2, 4, 6,
8, 10, 12, 14, 21, 28 post inoculation for blood chemis-
tries, virus titration, and neutralizing antibody titration.
Axillary or inguinal lymph nodes were surgically excised
on days 4, 6, 8, and 12 post inoculation for viral titer or
fixed in buffered formalin for histopathology and immu-
nohistochemical analysis. Monkeys were observed daily
for clinical disease. To determine LACV infectivity at low
doses, rhesus monkeys (n = 4) were inoculated with 101
or 103 PFU LACV/mosquito/1978-clone subcutaneously.
Blood samples were collected on days 0, 21, 28, and 42
post inoculation for neutralizing antibody titration.
Neutralization assay
Neutralizing antibody in mouse and monkey serum was
quantitated by a plaque reduction neutralization assay.
Test sera were heat inactivated (56°C for 30 minutes) and
serial 2-fold dilutions beginning at 1:5 or 1:10 were pre-
pared in OptiMEM (Invitrogen) supplemented with 2%
FBS, 50 µg/ml gentamicin, and 0.5% human albumin
(Talecris Biotherapeutics, Inc., Research Triangle Park,
NC). The homologous LACV was diluted to a final titer of
500 PFU/ml in the same diluent and 10% guinea pig com-
plement (Cambrex Bioscience Walkersville, Inc., Walkers-
ville, MD) was added to equal volumes of the serum
dilutions and mixed well. Serum/virus mixture was incu-
bated at 37°C for 30 minutes, added to confluent monol-
ayers of Vero cells, and incubated for 1 hour to allow virusVirology Journal 2008, 5:25 http://www.virologyj.com/content/5/1/25
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attachment. Cells were overlayed with 1% methylcellu-
lose and incubated for 5 days at 37°C. After incubation,
the overlay was removed, and the monolayers were
washed twice with PBS and stained with crystal violet to
allow for the enumeration of virus plaques. A 60%
plaque-reduction neutralization titer was calculated.
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